Chang D W, Wang B, Robb G L, Reece G P, Miller M J, Evans G R, Langstein H N, Kroll S S
Department of Plastic and Reconstructive Surgery at the University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Plast Reconstr Surg. 2000 Apr;105(5):1640-8. doi: 10.1097/00006534-200004050-00007.
The purpose of this study was to assess the effect of obesity on flap and donor-site complications in patients undergoing free transverse rectus abdominis myocutaneous (TRAM) flap breast reconstruction. All patients undergoing breast reconstruction with free TRAM flaps at our institution from February 1, 1989, through May 31, 1998, were reviewed. Patients were divided into three groups based on their body mass index: normal (body mass index <25), overweight (body mass index 25 to 29), obese (body mass index > or =30). Flap and donor-site complications in the three groups were compared. A total of 936 breast reconstructions with free TRAM flaps were performed in 718 patients. There were 442 (61.6 percent) normal-weight, 212 (29.5 percent) overweight, and 64 (8.9 percent) obese patients. Flap complications occurred in 222 of 936 flaps (23.7 percent). Compared with normal-weight patients, obese patients had a significantly higher rate of overall flap complications (39.1 versus 20.4 percent; p = 0.001), total flap loss (3.2 versus 0 percent; p = 0.001), flap seroma (10.9 versus 3.2 percent; p = 0.004), and mastectomy flap necrosis (21.9 versus 6.6 percent; p = 0.001). Similarly, overweight patients had a significantly higher rate of overall flap complications (27.8 versus 20.4 percent; p = 0.033), total flap loss (1.9 versus 0 percent p = 0.004), flap hematoma (0 versus 3.2 percent; p = 0.007), and mastectomy flap necrosis (15.1 versus 6.6 percent; p = 0.001) compared with normal-weight patients. Donor-site complications occurred in 106 of 718 patients (14.8 percent). Compared with normal-weight patients, obese patients had a significantly higher rate of overall donor-site complications (23.4 versus 11.1 percent; p = 0.005), infection (4.7 versus 0.5 percent; p = 0.016), seroma (9.4 versus 0.9 percent; p <0.001), and hernia (6.3 versus 1.6 percent; p = 0.039). Similarly, overweight patients had a significantly higher rate of overall donor-site complications (19.8 versus 11.1 percent; p = 0.003), infection (2.4 versus 0.5 percent; p = 0.039), bulge (5.2 versus 1.8 percent; p = 0.016), and hernia (4.3 versus 1.6 percent; p = 0.039) compared with normal-weight patients. There were no significant differences in age distribution, smoking history, or comorbid conditions among the three groups of patients. Obese patients, however, had a significantly higher incidence of preoperative radiotherapy and preoperative chemotherapy than did patients in the other two groups. A total of 23.4 percent of obese patients had preoperative radiation therapy compared with 12.3 percent of overweight patients and 12.4 percent of normal-weight patients; 34.4 percent of obese patients had preoperative chemotherapy compared with 24.5 percent of overweight patients and 17.7 percent of normal-weight patients. Multiple logistic regression analysis was used to determine the risk factors for flap and donor-site complications while simultaneously controlling for potential confounding factors, including the incidence of preoperative chemotherapy and radiotherapy. In summary, obese and overweight patients undergoing breast reconstruction with free TRAM flaps had significantly higher total flap loss, flap hematoma, flap seroma, mastectomy skin flap necrosis, donor-site infection, donor-site seroma, and hernia compared with normal-weight patients. There were no significant differences in the rate of partial flap loss, vessel thrombosis, fat necrosis, abdominal flap necrosis, or umbilical necrosis between any of the groups. The majority of overweight and even obese patients who undertake breast reconstruction with free TRAM flaps complete the reconstruction successfully. Both such patients and surgeons, however, must clearly understand that the risk of failure and complications is higher than in normal-weight patients. Patients who are morbidly obese are at very high risk of failure and complications and should avoid any type of TRAM flap breast reconstruction.
本研究的目的是评估肥胖对接受游离腹直肌肌皮瓣(TRAM瓣)乳房重建患者的皮瓣及供区并发症的影响。回顾了1989年2月1日至1998年5月31日在我院接受游离TRAM瓣乳房重建的所有患者。根据体重指数将患者分为三组:正常(体重指数<25)、超重(体重指数25至29)、肥胖(体重指数≥30)。比较三组的皮瓣及供区并发症情况。718例患者共进行了936例游离TRAM瓣乳房重建。其中体重正常者442例(61.6%),超重者212例(29.5%),肥胖者64例(8.9%)。936例皮瓣中有222例(23.7%)出现皮瓣并发症。与体重正常患者相比,肥胖患者皮瓣总体并发症发生率显著更高(39.1%对20.4%;p = 0.001),皮瓣完全坏死率(3.2%对0%;p = 0.001),皮瓣血清肿发生率(10.9%对3.2%;p = 0.004),以及乳房切除皮瓣坏死率(21.9%对6.6%;p = 0.001)。同样,与体重正常患者相比,超重患者皮瓣总体并发症发生率显著更高(27.8%对20.4%;p = 0.033),皮瓣完全坏死率(1.9%对0%;p = 0.004),皮瓣血肿发生率(0对3.2%;p = 0.007),以及乳房切除皮瓣坏死率(15.1%对6.6%;p = 0.001)。718例患者中有106例(14.8%)发生供区并发症。与体重正常患者相比,肥胖患者供区总体并发症发生率显著更高(23.4%对11.1%;p = 0.005),感染率(4.7%对0.5%;p = 0.016),血清肿发生率(9.4%对0.9%;p<0.001),以及疝发生率(6.3%对1.6%;p = 0.039)。同样,与体重正常患者相比,超重患者供区总体并发症发生率显著更高(19.8%对11.1%;p = 0.003),感染率(2.4%对0.5%;p = 0.039),隆起发生率(5.2%对1.8%;p = 0.016),以及疝发生率(4.3%对1.6%;p = 0.039)。三组患者在年龄分布、吸烟史或合并症方面无显著差异。然而,肥胖患者术前放疗和术前化疗的发生率显著高于其他两组患者。23.4%的肥胖患者接受了术前放疗,而超重患者为12.3%,体重正常患者为12.4%;34.4%的肥胖患者接受了术前化疗,而超重患者为24.5%,体重正常患者为